References
- Vaishya R , KhuranaV , PatelS , MitraAK. Long-term delivery of protein therapeutics. Expert Opin. Drug Deliv.12(3), 415–440 (2015).
- Dolan DE , GuptaS. PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. Cancer Control21(3), 231–237 (2014).
- Yu M , WuJ , ShiJ , FarokhzadOC. Nanotechnology for protein delivery: overview and perspectives. J. Control. Rel.240, 24–37 (2016).
- Tibbitt MW , DahlmanJE , LangerR. Emerging frontiers in drug delivery. J. Am. Chem. Soc.138(3), 704–717 (2016).
- Batista P , CastroPM , MadureiraAR , SarmentoB , PintadoM. Recent insights in the use of nanocarriers for the oral delivery of bioactive proteins and peptides. Peptides101, 112–123 (2018).
- Vaishya RD , KhuranaV , PatelS , MitraAK. Controlled ocular drug delivery with nanomicelles. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.6(5), 422–437 (2014).
- Li Z , LohXJ. Recent advances of using polyhydroxyalkanoate-based nanovehicles as therapeutic delivery carriers. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.9(3), e1429 (2017).
- Tammam SN , AzzazyHM , LamprechtA. Biodegradable particulate carrier formulation and tuning for targeted drug delivery. J. Biomed. Nanotechnol.11(4), 555–577 (2015).
- Allahyari M , MohitE. Peptide/protein vaccine delivery system based on PLGA particles. Hum. Vaccin. Immunother.12(3), 806–828 (2016).
- Ding D , ZhuQ. Recent advances of PLGA micro/nanoparticles for the delivery of biomacromolecular therapeutics. Mater. Sci. Eng. C92, 1041–1060 (2018).
- Bobo D , RobinsonKJ , IslamJ , ThurechtKJ , CorrieSR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm. Res.33(10), 2373–2387 (2016).
- Ansary RH , AwangMB , RahmanMM. Biodegradable poly (D, L-lactic-co-glycolic acid)-based micro/nanoparticles for sustained release of protein drugs-A review. Trop. J. Pharm. Res.13(7), 1179–1190 (2014).
- Danhier F , AnsorenaE , SilvaJM , CocoR , LeBreton A , PréatV. PLGA-based nanoparticles: an overview of biomedical applications. J. Control. Rel.161(2), 505–522 (2012).
- Anselmo AC , MitragotriS. An overview of clinical and commercial impact of drug delivery systems. J. Control. Rel.190, 15–28 (2014).
- Liu H , SlamovichEB , WebsterTJ. Less harmful acidic degradation of poly (lactic-co-glycolic acid) bone tissue engineering scaffolds through titania nanoparticle addition. Int. J. Nanomed.1(4), 541 (2006).
- Zhou P , AnT , ZhaoCet al. Lactosylated PLGA nanoparticles containing ϵ-polylysine for the sustained release and liver-targeted delivery of the negatively charged proteins. Int. J. Pharm.478(2), 633–643 (2015).
- Jordan F , NaylorA , KellyCA , HowdleSM , LewisA , IllumL. Sustained release hGH microsphere formulation produced by a novel supercritical fluid technology: in vivo studies. J. Control. Rel.141(2), 153–160 (2010).
- Peer D , KarpJM , HongS , FarokhzadOC , MargalitR , LangerR. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol.2(12), 751 (2007).
- Ye M , KimS , ParkK. Issues in long-term protein delivery using biodegradable microparticles. J. Control. Rel.146(2), 241–260 (2010).
- Park J , WrzesinskiSH , SternEet al. Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat. Mat.11(10), 895 (2012).